Sort   by:  
 Page size 
UnknownComparative Molecular Analysis of Gastrointestinal Adenocarcinomas.
We analyzed 921 adenocarcinomas of the esophagus, stomach, colon, and rectum to examine shared and distinguishing molecular characteristics of gastrointestinal tract adenocarcinomas (GIACs). Hypermutated tumors were distinct regardless of cancer type and comprised those enriched for insertions/delet...
S-EPMC5966039 | biostudies-literature
UnknownThiazolidinedione use and retinal fluid in the comparison of age-related macular degeneration treatments trials.

Background

Thiazolidinediones, commonly used antidiabetic medications, have been associated with an increased risk of development of diabetic macular oedema and increased vascular endothelial cell permeability. Macular neovascularisation in age-related macular degeneration (AMD) and associat...
S-EPMC10245276 | biostudies-literature
UnknownSporadic visual acuity loss in the Comparison of Age-Related Macular Degeneration Treatments Trials (CATT).

Purpose

To evaluate transient, large visual acuity (VA) decreases, termed sporadic vision loss, during anti-vascular endothelial growth factor treatment for neovascular age-related macular degeneration (AMD).

Design

Cohort within a randomized clinical trial.

Methods

setting: Co...
S-EPMC4301065 | biostudies-literature
UnknownPredominantly Persistent Intraretinal Fluid in the Comparison of Age-related Macular Degeneration Treatments Trials.

Purpose

To describe predominantly persistent intraretinal fluid (PP-IRF) and its association with visual acuity (VA) and retinal anatomic findings at long-term follow-up in eyes treated with pro re nata (PRN) ranibizumab or bevacizumab for neovascular age-related macular degeneration.

Des...

S-EPMC10282893 | biostudies-literature
UnknownRanibizumab and bevacizumab for neovascular age-related macular degeneration.

Background

Clinical trials have established the efficacy of ranibizumab for the treatment of neovascular age-related macular degeneration (AMD). In addition, bevacizumab is used off-label to treat AMD, despite the absence of similar supporting data.

Methods

In a multicenter, single-bl...
S-EPMC3157322 | biostudies-literature
UnknownMacular morphology and visual acuity in the comparison of age-related macular degeneration treatments trials.

Objective

To describe the effects of treatment for 1 year with ranibizumab or bevacizumab on macular morphology and the association of macular morphology with visual acuity (VA) in eyes with neovascular age-related macular degeneration (AMD).

Design

Prospective cohort study within a r...
S-EPMC3737287 | biostudies-literature
UnknownAngiographic Cystoid Macular Edema and Outcomes in the Comparison of Age-Related Macular Degeneration Treatments Trials.

Purpose

To describe morphologic and visual outcomes in eyes with angiographic cystoid macular edema (CME) treated with ranibizumab or bevacizumab for neovascular age-related macular degeneration (nAMD).

Design

Prospective cohort study within a randomized clinical trial.

Participant...

S-EPMC4808340 | biostudies-literature
UnknownBaseline predictors for one-year visual outcomes with ranibizumab or bevacizumab for neovascular age-related macular degeneration.

Objective

To determine the baseline predictors of visual acuity (VA) outcomes 1 year after treatment with ranibizumab or bevacizumab for neovascular age-related macular degeneration (AMD).

Design

Cohort study within the Comparison of Age-related Macular Degeneration Treatments Trials ...
S-EPMC3536921 | biostudies-literature
UnknownOutcomes in Eyes with Retinal Angiomatous Proliferation in the Comparison of Age-Related Macular Degeneration Treatments Trials (CATT).

Purpose

To compare baseline characteristics, visual acuity (VA), and morphologic outcomes between eyes with retinal angiomatous proliferation (RAP) and all other eyes among patients with neovascular age-related macular degeneration (NVAMD) treated with anti-vascular endothelial growth factor...
S-EPMC4766028 | biostudies-literature
UnknownSubretinal Hyperreflective Material in the Comparison of Age-Related Macular Degeneration Treatments Trials.

Purpose

To evaluate the association of subretinal hyperreflective material (SHRM) with visual acuity (VA), geographic atrophy (GA), and scar in the Comparison of Age-Related Macular Degeneration Treatments Trials (CATT).

Design

Prospective cohort study within a randomized clinical tri...
S-EPMC4549177 | biostudies-literature
Sort   by:  
 Page size